<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362658</url>
  </required_header>
  <id_info>
    <org_study_id>RES0027887</org_study_id>
    <nct_id>NCT03362658</nct_id>
  </id_info>
  <brief_title>Novel MRI Biomarkers for Monitoring Disease Progression in ALS</brief_title>
  <official_title>Novel MRI Biomarkers for Monitoring Disease Progression in ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Western University, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <brief_summary>
    <textblock>
      Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques
      can provide an objective measure of degeneration (a &quot;biomarker&quot;) by examining brain
      structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques
      that could improve our understanding of ALS and provide a means to diagnose it sooner and
      monitor its progression. Importantly, we expect these techniques to improve how new drugs are
      tested, which may lead to the more rapid discovery of a treatment for ALS.

      Each participant will have 3 MRI scans over a period of 8 months, along with neurological and
      cognitive evaluations. Study visits will take 2 - 3 hours. MRI is a safe technique that does
      not involve radiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current clinical measures of disease burden have suboptimal sensitivity to disease
      progression in ALS. A biomarker would play an essential role in the evaluation of novel
      therapeutics, leading to the realization of effective treatments faster. Magnetic resonance
      imaging (MRI) holds promise as a non-invasive source of biomarkers in ALS. In this study data
      is collected from a national imaging platform (the Canadian ALS Neuroimaging Consortium
      [CALSNIC]) using standardized MRI and clinical protocols.

      CALSNIC was founded with the objective to validate MRI biomarkers on a standardized
      multi-centre platform. CALSNIC is a multidisciplinary group of scientists at 7 centres across
      Canada. The first CALSNIC study entitled &quot;MRI Biomarkers in ALS&quot; (CALSNIC-1) is ongoing and
      slated to finish recruitment in 2017.

      This study (&quot;Novel MRI Biomarkers for Monitoring Disease Progression in ALS&quot;, CALSNIC-2) is a
      new project that will evaluate novel MRI biomarkers using advanced imaging acquisition and
      processing methods. The specific aims of CALSNIC-2 are 1) to establish a standardized MRI and
      clinical protocol across the 7 centres, and 2) to validate MRI measures with clinical
      measures of disease burden and progression.

      It is anticipated that the project will lead to the discovery of MR-based biomarkers of
      cerebral degeneration that can be applied across different centres and hence, can assist with
      drug development. Secondly, this project will expand CALSNIC to include more centres and
      provide opportunities for collaborative and multidisciplinary translational research on a
      national scale.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cortical thickness in millimetres.</measure>
    <time_frame>8 months</time_frame>
    <description>This primary analysis will evaluate neuronal integrity at baseline and specified follow up periods. Patients and controls scans will be compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in DTI indices (unitless).</measure>
    <time_frame>8 months</time_frame>
    <description>This primary analysis will evaluate white matter integrity at baseline and specified follow up periods. Patients and controls scans will be compared.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Motor Neuron Disease</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>ALS patients (as well as patients with other related disorders such PLS, PMA, and ALS-FTD) will be recruited from ALS clinics under the direction of neurologists who are participating in this study. ALS patients should meet research criteria for suspected, possible, probable, probable laboratory supported, or definite ALS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy controls who are age and gender matched to patients.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients with a diagnosis of motor neuron disease (MND). This includes the diagnoses
             of amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), and
             progressive muscular atrophy (PMA).

          2. Patients with frontotemporal dementia (FTD) with or without motor neuron signs.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a suspected or confirmed diagnosis as described in Study Populations

          -  For those with a diagnosis of ALS, patients will be considered with an El Escorial
             classification of suspected, possible, probable, probable lab-supported, and definite
             ALS.

          -  Patients 18 years of age or older

          -  Healthy controls over the age of 40.

          -  Be able to lie in an MRI machine for approximately 60 minutes

        Exclusion Criteria:

          -  Subjects with psychiatric/CNS illnesses such as Major Depressive Disorder,
             Schizophrenia, and Bipolar disorder.

          -  Subjects with significant head injury or other neurological disease (stroke, brain
             tumour).

          -  Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign
             body.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Kalra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FRCPC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dennell M Mah, BA</last_name>
    <phone>780-248-1805</phone>
    <email>dennell.mah@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brian Steele</last_name>
    <phone>780-248-1805</phone>
    <email>bjsteele@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Stark</last_name>
      <phone>305-243-7613</phone>
      <email>jhs55@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Manso</last_name>
      <email>a.manso@miami.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Calgary / Heritage Medical Research Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Hodgkinson</last_name>
      <phone>403-210-7303</phone>
      <email>vhodgkin@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Janet Petrillo</last_name>
      <phone>403-210-7006</phone>
      <email>japetril@ucalgary.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennell Mah, BA</last_name>
      <phone>780-248-1805</phone>
      <email>dennell.mah@ualberta.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of British Columbia / GF Strong Rehab Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 2G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marife Fabros, RN</last_name>
      <phone>604-737-6319</phone>
      <email>marife.fabros@vch.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western University / London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Piechowicz</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>34858</phone_ext>
      <email>Christine.Piechowicz@lhsc.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Toronto / Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Pham</last_name>
      <phone>416-480-5618</phone>
      <email>Shirley.Pham@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Serena Soleimani</last_name>
      <phone>416-480-6860</phone>
      <phone_ext>87561</phone_ext>
      <email>serena.soleimani@sunnybrook.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>McGill University / Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Saunders</last_name>
      <phone>514-398-6526</phone>
      <email>natalie.saunders@mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kristiana Salmon</last_name>
      <phone>514-398-1779</phone>
      <email>kristiana.salmon@mcgill.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Simard, BSc</last_name>
      <phone>418-649-0252</phone>
      <phone_ext>63559</phone_ext>
      <email>alexandra.simard@crchudequebec.ulaval.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Sanjay Kalra</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>MRI</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

